Supreme Court to hear Amgen appeal on Repatha spat with Sanofi, Regeneron
Douglas Rissing         

The US Supreme Court has decided to hear an appeal filed by Amgen (NASDAQ:AMGN) over a lower court's decision to invalidate key patents on its cholesterol medication Repatha (evolocumab) following a challenge by Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN).
A federal appeals court earlier denied Amgen's attempt to get Sanofi (SNY) and Regeneron's (REGN) rival cholesterol biologic medicine, Praluent (alirocumab), off the market, Bloomberg Law reported.
Both drugs are considered PCSK9 inhibitors.
The Justice Department had requested the High Court deny the appeal, Bloomberg Law reported.
See why Seeking Alpha contributor Stock Waves views Amgen (AMGN) as a buy.